This is a preview of subscription content, log in via an institution to check access.
Notes
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus-4 trial
glucagon-like peptide-1 receptor agonist
Reference
Risebrough NA, et al. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. Clinical Therapeutics : 30 Oct 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.08.015
Rights and permissions
About this article
Cite this article
Oral semaglutide a cost-effective option for patients with uncontrolled T2DM. PharmacoEcon Outcomes News 891, 20 (2021). https://doi.org/10.1007/s40274-021-08178-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08178-8